Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: MRD detection and clinical outcomes of patients treated with CAR-T cells.

Data availability

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).


  1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591–8.

    CAS  Article  Google Scholar 

  2. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

    CAS  Article  Google Scholar 

  3. Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017;23:3297–306.

    CAS  Article  Google Scholar 

  4. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.

    CAS  Article  Google Scholar 

  5. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–31.

    CAS  Article  Google Scholar 

  6. Giusti GNN, Jotta PY, Lopes CO, Ganazza MA, de Azevedo AC, Brandalise SR, et al. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia. Br J Haematol. 2020;189:e150–4.

    CAS  Article  Google Scholar 

  7. Hultcrantz M, Rustad EH, Yellapantula V, Arcila M, Ho C, Syed MH, et al. Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. Blood Cancer J. 2020;10:76.

    Article  Google Scholar 

  8. Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015;125:3501–8.

    CAS  Article  Google Scholar 

  9. Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131:1350–9.

    CAS  Article  Google Scholar 

  10. Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transpl. 2014;20:1307–13.

    CAS  Article  Google Scholar 

  11. Kotrova M, van der Velden VHJ, van Dongen JJM, Formankova R, Sedlacek P, Bruggemann M, et al. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transpl. 2017;52:962–8.

    CAS  Article  Google Scholar 

  12. Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Disco. 2022;3:66–81.

    Article  Google Scholar 

Download references


This work was supported by the 973 Program (Project No. 2015-CB964900), the Natural Science Foundation of China (Project No. 81770201 and No. 81730008). This trial was registered at as # ChiCTR1800018468 and # ChiCTR-OCC-15007008.

Author information

Authors and Affiliations



YH, HZ and MS collected the patients’ data and drafted the manuscript. TS, YXH and HH conceived and designed the study. YXH revised the manuscript along with GW, WW and AHC and these individuals were responsible for the treatment of these patients. All authors checked and approved the final manuscript.

Corresponding authors

Correspondence to Tao Sun, Yongxian Hu or He Huang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Huang, Y., Zhao, H., Shao, M. et al. Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. Bone Marrow Transplant (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:


Quick links